GE HealthCare gets FDA nod for True Definition DL CT software

GE HealthCare (GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for True Definition DL, a deep-learning image reconstruction tool for CT imaging.

True Definition DL is designed for high-resolution imaging in pulmonary, musculoskeletal, and inner ear applications. It enhances spatial resolution across multiple directions, integrates artifact suppression, and supports a high-definition mode to improve visibility of fine anatomical structures such as small airways, pulmonary nodules, and trabecular bone patterns. 

The tool also offers a 1024 matrix for high-resolution display and enables chest imaging in under one second, the company said.

True Definition DL joins GEHC's existing deep-learning CT reconstruction portfolio, which includes TrueFidelity DL, introduced in 2019 as the company's first deep-learning image reconstruction tool for whole-body imaging, and True Enhance DL, which improves contrast from standard single-energy CT scans using a neural network trained on dual-energy imaging data. 

The tools are available on the Revolution Apex and Revolution Vibe CT platforms for both new installations and in-field upgrades, GEHC said.